A Pharmacokinetics Study of GZR33 Injection at Different Injection Sites
A Randomized, Open-Label, Three-Period Crossover Clinical Study to Evaluate the Pharmacokinetics and Safety of GZR33 Injection Administered at Different Injection Sites in Healthy Participants
This trial is conducted in China. This study will be conducted to evaluate the pharmacokinetics and safety of GZR33 Injection administered at different injection sites in healthy participants.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Kunlin Li
- Phone Number: 010-80595000
- Email: Kunlin.li@ganlee.com
Study Locations
-
-
-
Beijing, China
- Gan & Lee Pharmaceuticals
-
Contact:
- Kunlin Li
- Phone Number: 010-80595000
- Email: Kunlin.li@ganlee.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed the informed consent form (ICF) prior to study procedures, fully understood the study content, procedures and potential adverse reactions, and agreed to comply with the study protocol.
- Aged 18 to 45 years (inclusive, based on the date of ICF ); male or female.
Exclusion Criteria:
- History of atopic diathesis, or allergic diseases such as bronchial asthma, urticaria, and eczema; known hypersensitivity or intolerance to the investigational product, its analogous products, or excipients.
- Positive screening test for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), treponema pallidum antibody (TP-Ab).
- Participation in another clinical trial of investigational medicinal products or medical devices with receipt of study treatment within 3 months prior to screening.
- Participants who donated blood or blood product (>400 mL) or significant blood loss (>200 mL) within 6 months prior to screening, or plan to donate blood or blood products during the study.
- History of substance abuse or illicit drug use within 1 year prior to screening, or positive drug abuse screening test.
- Average daily tobacco consumption of more than 5 cigarettes within 3 months prior to screening, or inability to abstain from tobacco-containing products (cigarettes, chewing tobacco, etc.) during the study.
- History of vasovagal syncope related to needle or blood exposure, or difficult venous access for blood collection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: GZR33 Injection-Abdomen
Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions. |
Administered subcutaneously (s.c.) |
|
Experimental: GZR33 Injection-Upper Arm
Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions. |
Administered subcutaneously (s.c.) |
|
Experimental: GZR33 Injection- Thigh
Participants will receive a single-dose administration of GZR33 Injection(s.c. inthe abdomen , the upper arm and the thigh) on different occasions. |
Administered subcutaneously (s.c.) |
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AUC₀-₁₂₀ h
Time Frame: 0 hours to 120 hours after study drug administration
|
0 hours to 120 hours after study drug administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
AUC₀-∞
Time Frame: 0 hours to 120 hours after study drug administration
|
0 hours to 120 hours after study drug administration
|
|
Cmax
Time Frame: 0 hours to 120 hours after study drug administration
|
0 hours to 120 hours after study drug administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- GZR33-T2D-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.